GYNAZOLE-1

Post-LOE

butoconazole nitrate

Design Pharmaceuticals

ANDAVAGINALCREAM

Approved

May 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

GYNAZOLE-1 (butoconazole nitrate) by Design Pharmaceuticals is clinical pharmacology following vaginal administration of butoconazole nitrate vaginal cream, 2% to 3 women, 1. First approved in 2012.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Following vaginal administration of butoconazole nitrate vaginal cream, 2% to 3 women, 1.7% (range 1.3-2.2%) of the dose was absorbed on average. Peak plasma levels (13.6-18.6 ng radioequivalents/mL of plasma) of the drug and its metabolites are attained between 12 and 24…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on GYNAZOLE-1 at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.